BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32434180)

  • 1. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
    Tanaka T; Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Oncology; 2020; 98(9):621-629. PubMed ID: 32434180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
    Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
    Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.
    An J; Lee KS; Kim KM; Park DH; Lee SS; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS
    Clin Mol Hepatol; 2017 Jun; 23(2):160-169. PubMed ID: 28506055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
    McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
    Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory?
    Park J; Kim HC; Lee JH; Cho E; Kim M; Hur S; Jae HJ; Lee M; Chung JW
    Eur Radiol; 2018 Apr; 28(4):1540-1550. PubMed ID: 29124380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
    Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
    Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.
    Zhang Y; Fan W; Wang Y; Huang G; Li J
    Cancer Control; 2019; 26(1):1073274819872216. PubMed ID: 31466465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion.
    Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Nakatani M; Kariya S; Yamaguchi T; Yoshida K; Yoshii K; Sekimoto M
    Cancer Invest; 2022 Jan; 40(1):81-89. PubMed ID: 34236269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials.
    Cabibbo G; Cucchetti A; Cammà C; Casadei-Gardini A; Celsa C; Emanuele Maria Rizzo G; Johnson P; Ercolani G
    Future Oncol; 2019 Oct; 15(29):3411-3422. PubMed ID: 31588789
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
    Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
    Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.